Signup Crypto ETF Stocks News

Wellgistics Health Achieves SOC 2 Type 1 Compliance, Strengthening Security for AI-Driven Pharmacy Solutions and Employer-Based Healthcare Models

TAMPA, FL, March 18, 2025 ( GLOBE NEWSWIRE ) -- Wellgistics Health, Inc. ( NASDAQ: WGRX ) ( "Wellgistics Health" ) , a provider of pharmacy solutions and healthcare technology, has successfully completed a third-party audit and achieved SOC 2 Type 1 compliance.

Source: www.globenewswire.com
March 18, 2025 | 11:40:00
Category: News

Kering: 2024 Universal Registration Document available

Press release_2024 Universal Registration Document ...

Source: www.globenewswire.com
March 18, 2025 | 11:44:00
Category: News

Avicanna To Hold Full Year 2024 Earnings Conference Call

TORONTO, March 18, 2025 ( GLOBE NEWSWIRE ) -- Avicanna Inc. ( "Avicanna" or "Company" ) ( TSX: AVCN ) ( OTCQX: AVCNF ) ( FSE: 0NN ) , a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, invites interested ...

Source: www.globenewswire.com
March 18, 2025 | 11:44:00
Category: News

Avicanna To Hold Full Year 2024 Earnings Conference Call - Avicanna ( OTC:AVCNF )

TORONTO, March 18, 2025 ( GLOBE NEWSWIRE ) -- Avicanna Inc. ( "Avicanna" or "Company" ) AVCN AVCNF 0NN, a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, invites interested parties to participate in a ...

Source: www.benzinga.com
March 18, 2025 | 11:44:00
Category: News

Worksport Believes Market Valuation Does Not Fully Reflect Business Fundamentals; Targets Cash Flow Positivity and Meaningful Growth in 2025

West Seneca, New York, March 18, 2025 ( GLOBE NEWSWIRE ) -- Worksport Ltd. ( NASDAQ: WKSP ) ( "Worksport" or the "Company" ) , a U.S. based manufacturer and innovator of hybrid and clean energy solutions for the light truck, overlanding, and global consumer goods sectors, today shares proactive ...

Source: www.globenewswire.com
March 18, 2025 | 11:45:00
Category: News

EXCLUSIVE: Indaptus Therapeutics Starts Phase 1 Combination Study of Decoy20 With BeiGene's Cancer Drug For Advanced Solid Tumors - Indaptus Therapeutics ( NASDAQ:INDP )

Indaptus began a new expansion phase of its Decoy20 trial, combining it with BeiGene's tislelizumab to assess safety and anti-tumor activity The company expects its cash reserves to fund operations into Q2 2025 after securing a $20 million equity line with Yorkville.

Source: www.benzinga.com
March 18, 2025 | 11:45:44
Category: News

Russian Oil Firms Using Bitcoin, Ethereum to Dodge Sanctions

Sanctions evasion is proving increasingly "challenging" at scale for Russian firms, blockchain analytics firm Chainalysis told Decrypt.

Source: decrypt.co
March 18, 2025 | 11:46:03
Category: News

How To Earn $500 A Month From General Mills Stock Ahead Of Q3 Earnings - General Mills ( NYSE:GIS )

A more conservative goal of $100 monthly dividend income would require 500 shares of General Mills. An investor would need to own $152,350 worth of General Mills to generate a monthly dividend income of $500. Next: Get access to a new market-moving chart every day featuring a stock flashing ...

Source: www.benzinga.com
March 18, 2025 | 11:49:27
Category: News

Volkswagen's Audi To Slash Up To 7,500 Jobs By 2029 To Boost Competitiveness - Volkswagen ( OTC:VWAGY )

Audi to invest €8 billion in its German plants. Join Nic Chahine live on Wednesday, March 19, at 6 PM ET for a step-by-step breakdown of how to to capitalize on post-Fed volatility and manage risk in this fast-moving market. Register for this free strategy session today.

Source: www.benzinga.com
March 18, 2025 | 11:54:22
Category: News

ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study - ZyVersa Therapeutics ( NASDAQ:ZVSA )

In obesity-associated cardiomyopathy ( OAC ) , heart muscle is structurally and functionally abnormal, impairing the ability to effectively pump blood. Five-year survival rate is less than 50%, with congestive heart failure and sudden cardiac death predominant causes of death.

Source: www.benzinga.com
March 18, 2025 | 11:57:00
Category: News

© Natavest 2025 - 2026